Saltar al contenido
Merck

Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Indian journal of ophthalmology (2013-08-09)
Vinay Agrawal
RESUMEN

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
(−)-Riboflavina, from Eremothecium ashbyii, ≥98%
Supelco
Riboflavina (B2), analytical standard
Sigma-Aldrich
(−)-Riboflavina, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Supelco
(−)-Riboflavina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-Riboflavina, meets USP testing specifications
USP
(−)-Riboflavina, United States Pharmacopeia (USP) Reference Standard
(−)-Riboflavina, European Pharmacopoeia (EP) Reference Standard
(−)-Riboflavina, European Pharmacopoeia (EP) Reference Standard